Evidence map›Paper›PMID 41369208›Full record

ArticlemBio2026

Antibody responses following COVID-19 vaccination and breakthrough infections in naïve and convalescent individuals suggest imprinting to the ancestral strain of SARS-CoV-2.

Siddhartha Mahanty, Emily M Eriksson, Peta Edler, Francesca Mordant, Nicholas Kiernan-Walker, David J Price, Sabine Braat, Eamon Conway, Vanessa Bryant, Honghua Ding and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Siddhartha Mahanty *Department of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-1068-0524
Emily M Eriksson *Division of Population, Health and Immunity, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.ORCID 0000-0002-7851-973X
Peta EdlerDepartment of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Francesca MordantDepartment of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Nicholas Kiernan-WalkerDivision of Population, Health and Immunity, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
David J PriceDepartment of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Sabine BraatDepartment of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Eamon ConwayDivision of Population, Health and Immunity, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Vanessa BryantDepartment of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.
Honghua DingDepartment of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Leo Yi Yang LeeDepartment of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Louise RandallDepartment of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Ramin MazhariDivision of Population, Health and Immunity, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Ivo MuellerDivision of Population, Health and Immunity, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Kanta SubbaraoDepartment of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-1713-3056

Funding

National Health and Medical Research Council 1043345National Health and Medical Research Council APP1177174National Health and Medical Research Council IRIISSNational Institute of Allergy and Infectious Diseases 88SN272201400005CNIH HHS HHSN272201400005CWHO Unity Funds 2020/1085469-0
6 · The paper itself

Abstract

The binding and neutralizing activity of SARS-CoV-2 antibodies are important correlates of protection of current COVID-19 vaccines. SARS-CoV-2 exposure status and COVID-19 vaccine types can influence these responses and the breadth of cross-reactivity to variants. In this longitudinal cohort study, we used SARS-CoV-2-specific multiplex Luminex antibody assays and live virus neutralization of ancestral (VIC01/2020), Delta and Omicron (BA1, BA2, and BA5) SARS-CoV-2 variants to compare antigen-specific binding, and neutralizing antibody (nAb) responses to primary vaccination (two doses) of adenovirus vectored (AdVV) or mRNA vaccines followed by a booster dose of mRNA vaccine in convalescent (

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesSARS-CoV-2AdultAgedAntibodies, NeutralizingBreakthrough InfectionsConvalescenceFemaleHumansImmunization, SecondaryLongitudinal StudiesMaleMiddle AgedVaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccinesbreakthrough infectionCOVID-19 vaccinesneutralizing antibodySARS-CoV-2

Identifiers

PMID41369208
PMCPMC12802276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.